The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Clague Laura since 2008.
This trader's CIK number is 1388773.
At the time of last reporting, Clague Laura was the Chief Financial Officer of Travere Therapeutics, Inc.. (stock ticker symbol TVTX).
Also see all insider trading activities at Travere Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | TVTX | 0 | $0 | 13,001 | $338,275 | 0 | $0 |
| 2021 | TVTX | 0 | $0 | 17,157 | $459,278 | 0 | $0 |
| 2020 | TVTX | 0 | $0 | 32,527 | $696,270 | 0 | $0 |
| 2019 | TVTX | 0 | $0 | 4,533 | $89,199 | 0 | $0 |
| 2018 | TVTX | 0 | $0 | 15,000 | $347,379 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | GNSS | 0 | $0 | 13,716 | $43,068 | 70,000 | $109,700 |
| 2021 | GNSS | 0 | $0 | 5,456 | $40,467 | 20,000 | $40,400 |
| 2020 | GNSS | 0 | $0 | 0 | $0 | 30,000 | $0 |
| 2019 | GNSS | 0 | $0 | 0 | $0 | 25,000 | $0 |
| 2018 | GNSS | 0 | $0 | 0 | $0 | 25,000 | $0 |
| 2017 | GNSS | 0 | $0 | 0 | $0 | 25,000 | $0 |
| 2013 | GNSS | 0 | $0 | 9,400 | $14,476 | 30,000 | $14,400 |
| 2008 | GNSS | 2,000 | $870 | 0 | $0 | 0 | $0 |
1. Travere Therapeutics, Inc. (TVTX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-05-10 | TVTX | Sale | 825 | 21.51 | 17,745 |
| 2022-05-11 | TVTX | Sale | 1,375 | 21.51 | 29,576 |
| 2022-01-31 | TVTX | Sale | 1,238 | 27.40 | 33,921 |
| 2022-01-24 | TVTX | Sale | 2,063 | 24.98 | 51,533 |
| 2022-01-11 | TVTX | Sale | 7,500 | 27.40 | 205,500 |
| 2021-08-17 | TVTX | Sale | 1,407 | 17.12 | 24,085 |
| 2021-05-12 | TVTX | Sale | 2,000 | 19.46 | 38,920 |
| 2021-05-11 | TVTX | Sale | 2,000 | 19.14 | 38,280 |
| 2021-02-05 | TVTX | Sale | 2,250 | 31.41 | 70,672 |
| 2021-02-08 | TVTX | Sale | 2,250 | 31.58 | 71,055 |
| 2021-02-03 | TVTX | Sale | 3,625 | 28.91 | 104,798 |
| 2021-02-02 | TVTX | Sale | 3,625 | 30.75 | 111,468 |
| 2020-11-24 | RTRX | Sale | 3,750 | 23.86 | 89,475 |
| 2020-11-25 | RTRX | Sale | 3,750 | 22.72 | 85,200 |
| 2020-11-16 | RTRX | Sale | 7,500 | 23.98 | 179,812 |
| 2020-11-13 | RTRX | Sale | 7,500 | 23.61 | 177,075 |
| 2020-09-23 | RTRX | Sale | 1,500 | 18.48 | 27,720 |
| 2020-09-22 | RTRX | Sale | 1,500 | 18.59 | 27,885 |
| 2020-05-11 | RTRX | Sale | 1,250 | 14.95 | 18,687 |
| 2020-05-12 | RTRX | Sale | 1,777 | 17.07 | 30,336 |
| 2020-03-10 | RTRX | Sale | 4,000 | 15.02 | 60,080 |
| 2019-05-15 | RTRX | Sale | 1,250 | 17.78 | 22,225 |
| 2019-05-16 | RTRX | Sale | 1,250 | 18.71 | 23,387 |
| 2019-02-12 | RTRX | Sale | 1,016 | 21.50 | 21,844 |
| 2019-02-11 | RTRX | Sale | 1,017 | 21.38 | 21,743 |
| 2018-12-20 | RTRX | Sale | 3,750 | 22.08 | 82,803 |
| 2018-12-21 | RTRX | Sale | 3,750 | 22.00 | 82,518 |
| 2018-11-14 | RTRX | Sale | 3,750 | 24.08 | 90,315 |
| 2018-11-15 | RTRX | Sale | 3,750 | 24.46 | 91,743 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-04-27 | GNSS | Option Ex | 50,000 | 1.33 | 66,500 |
| 2022-02-23 | GNSS | Option Ex | 20,000 | 2.16 | 43,200 |
| 2022-02-23 | GNSS | Sale | 13,716 | 3.14 | 43,068 |
| 2021-03-10 | GNSS | Option Ex | 20,000 | 2.02 | 40,400 |
| 2021-03-10 | GNSS | Sale | 5,456 | 7.42 | 40,467 |
| 2020-03-12 | LRAD | Option Ex | 30,000 | .00 | 0 |
| 2019-03-20 | LRAD | Option Ex | 25,000 | .00 | 0 |
| 2018-03-14 | LRAD | Option Ex | 25,000 | .00 | 0 |
| 2017-05-17 | LRAD | Option Ex | 25,000 | .00 | 0 |
| 2013-09-04 | LRAD | Option Ex | 30,000 | .48 | 14,400 |
| 2013-09-04 | LRAD | Sale | 9,400 | 1.54 | 14,476 |
| 2008-12-11 | ATCO | Buy | 2,000 | .43 | 870 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Clague Laura (Chief Financial Officer of Travere Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.